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Abstract
Background: Acute HIV infection (AHI) is a critical phase of infection when irreparable damage to the immune system
occurs and subjects are very infectious. We studied subjects with AHI prospectively to develop better treatment and public
health interventions.
Methods: Cross-sectional screening was employed to detect HIV RNA positive, antibody negative subjects. Date of HIV
acquisition was estimated from clinical history and correlated with sequence diversity assessed by single genome
amplification (SGA). Twenty-two cytokines/chemokines were measured from enrollment through week 24.
Results: Thirty-seven AHI subjects were studied. In 7 participants with limited exposure windows, the median exposure to
HIV occurred 14 days before symptom onset. Lack of viral sequence diversification confirmed the short duration of infection.
Transmission dates estimated by SGA/sequencing using molecular clock models correlated with transmission dates
estimated by symptom onset in individuals infected with single HIV variants (mean of 28 versus 33 days). Only 10 of 22
cytokines/chemokines were significantly elevated among AHI participants at enrollment compared to uninfected controls,
and only 4 participants remained seronegative at enrollment.
Discussion: The results emphasize the difficulty in recruiting subjects early in AHI. Viral sequence diversity proved accurate
in estimating time of infection. Regardless of aggressive screening, peak viremia and inflammation occurred before
enrollment and potential intervention. Given the personal and public health importance, improved AHI detection is urgently
needed.
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Introduction
Acute human immunodeficiency virus (HIV) infection (AHI)
constitutes the first stage of HIV infection. After HIV exposure local
infection is established at transmission sites, and the virus spreads to
regional lymph nodes and disseminates.[1] An expansion phase
follows with exponential HIV replication in most individuals to peaks
which can exceed 10 million copies/ml.[2] Subsequently, cell-
mediatedimmuneresponses[3,4,5]leadtodecreasedviralreplication.
The impact of events during AHI on the course of disease has
been well-established[6,7,8] emphasizing the need for insight into
virus-host interactions during AHI.[9] People with AHI represent
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19617a major risk for secondary HIV-1 transmission,[10,11,12]
providing additional impetus for strategies to modulate AHI.
However, AHI detection remains difficult, and only a small
number of acutely infected subjects have been studied.
To find subjects immediately after HIV acquisition we
employed cross-sectional screening to identify HIV RNA positive,
seronegative subjects,[13] corresponding to the viral expansion
phase.[14] At this time viral population in vivo has diverged
minimally from the transmitted sequence(s), since few rounds of
viral replication have occurred.[15] We correlated history of HIV
exposure with HIV sequence diversity as a potential biomarker for
date of infection. We examined plasma cytokine levels and the
effects of antiretroviral therapy (ART) on these markers of
inflammation. The results provide a clear, prospective picture of
patients with AHI, and emphasize the difficulty in recruiting
subjects very early in AHI due to missed opportunities for earlier
diagnosis and diagnostic delays. Accordingly, wider awareness of
the clinical presentation by medical providers as well as more
rapid strategies to diagnosis AHI are needed.
Methods
Ethics Statement
This study and the additional studies in which participants
could co-enroll on (see below) were approved by the University of
North Carolina at Chapel Hill (UNC) and Duke University
Institutional Review Boards. A separate informed consent was
obtained for each study in which the subject participated.
Recruitment
The state of North Carolina (NC) has an ongoing program to
identify people in acute HIV infection (AHI) as part of its statewide
HIV surveillance program. Since 2002, persons HIV-tested at
approximately 135 publicly-funded sites have been included in the
Screening and Tracing Active Transmission (STAT) Program.[13]
Additional cases of acute HIV infection are identified through
screening performed at primary care testing sites such as urgent
care clinics, emergency departments, private doctor’s offices and
infectious disease clinics (Table 1), usually due to symptoms
suggesting acute retroviral syndrome. Individuals meeting the
following criteria from either referral source are referred: 1) EIA
negative or indeterminate and positive NAT, 2) EIA indeterminate
and positive EIA confirmation, and 3) EIA positive with
seronegative documentation within the preceding 30 days. AHI
diagnosis is the date of the first test detecting the presence of HIV,
and not the date that the individual is notified of the result. When
possible, screening samples were obtained for quantitative viral
load and Western blot.
Following identification of suspected or confirmed acute HIV
cases through rapid notification from the STAT program to NC
Table 1. Demographic and clinical characteristics of participants with acute HIV infection and seronegative controls.
Characteristic AHI Participants HIV Negative Controls P value
Age, years; median (range) 32 (17–66) 34 (18–54) 0.5
Gender, N (%) Male 33 (89.2) 17 (80.9) 0.4
Female 4 (10.8) -
Risk category
a, N (%) Heterosexual 8 (21.6) - -
MSM/Bisexual
b 29 (78.4) -
Race, N (%) Black 18 (48.7) 6 (28.6)
White 17 (46.0) 14 (66.7) 0.2
Other 2 (5.4) 1 (4.8)
STI at diagnosis, N (%)
c Yes
d 7 (18.9) 4 (19.1) 0.99
No 30 (81.1) 17 (80.9)
Any symptom reported, N (%) Yes 35 (94.6) - -
No 2 (5.4) - -
Site of Diagnosis, N (%)
Health Department/STD Clinic 21 (56.8) - -
ED/Urgent Care 7 (18.9) - -
Primary Care Physician 7 (18.9) - -
Other
f 2 (5.4) - -
Enrollment CD4 T-cell count, cells/mm
3; median (range) 541(13–1012) - -
Nadir CD4 T-cell count, cells/mm
3; median (range) 487 (13–882) - -
HIV RNA at AHI ´ diagnosis, copies/ml
e ; median (range) 592,690 (3,144-84,545,454) - -
Time from AHI diagnosis to enrollment, days; median (range) 16 (4–42) - -
aNo participants endorsed injection drug use.
bMSM = Men who have sex with men.
cSTI = sexually transmitted infection
dSyphilis (n=2), gonorrhea (n=1), Chlamydia trachomatis (n=1), non-gonococcal urethritis (n=1) and genital ulcer disease (n=1). One female subject was diagnosed
with concurrent bacterial vaginosus, pelvic inflammatory disease, trichomoniasis and genital ulcer disease.
eViral Loads .750,000 copies/ml were included in the calculation of the medians as equal to 750,000 copies/ml unless sample was diluted and retested, in which case
the true value was used.
fOther diagnosis sites included student health and drug treatment program
doi:10.1371/journal.pone.0019617.t001
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NC DHHS Disease Intervention Specialists (DIS) perform the
initial interviews, confirmatory tests and make referrals to care
within 72 hours after receiving a report. In addition to standard
information about the testing sites, reasons for HIV testing,
demographics, HIV testing history and risk factors, DIS also
collect detailed information about symptoms, risk behavior and
partnerships for the STAT program [13]. Written informed
consent for the use of personal de-identified information is
obtained from all AHI participants.
Enrollment
Suspected and confirmed AHI cases are referred for evaluation
at UNC or Duke University, and can enroll in the Center for
HIV/AIDS Vaccine Immunology (CHAVI) 001 Study: Acute
HIV Infection Prospective Cohort if they meet AHI criteria
defined as: 1) EIA negative and positive NAT; 2) positive EIA and
positive NAT with a negative/indeterminate Western blot; 3)
positive EIA, positive Western blot and EIA negative documen-
tation within the preceding 45 days. Subjects can also co-enroll in
a treatment study with co-formulated emtricitabine, tenofovir and
efavirenz (Atripla) initiated within 30 days of AHI diagnosis and
continued for 48 weeks.[16] Untreated acute subjects can enroll
on another AHI longitudinal study. Sample collection begins at
enrollment and at weeks 1, 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 84
and 96. Clinical and symptom data collected from all three studies
were used in data analysis for this study. A separate informed
consent was obtained for each study in which the subject
participated. HIV negative control subjects were recruited via
flyers placed at Duke Medical Center and the UNC Hospitals
campus and local health departments. HIV negative controls did
not differ from the AHI subjects in age, gender, race, or history of
STIs using a non-parametric Mann-Whitney U-test (Table 1).
Estimation of HIV risk exposure
To characterize estimated date of infection in AHI subjects, we
reviewed charts to elicit exposure dates with all reported sex
partners and partner HIV status in the 8 weeks preceding AHI
diagnosis. Estimated-date-of-infection was defined as a function
of the likelihood of the HIV source and timing of sexual contact
with the suspected source. When available, single genome
amplification (SGA) and DNA sequencing confirmed transmis-
sion partners. Acute retroviral syndrome (ARS) symptom data
were reviewed to determine onset and resolution dates, including:
fever, headache, night sweats, weight loss, myalgias, arthralgias,
fatigue, rash, odynophagia, lymphadenopathy, oral candidiasis,
mouth ulcers/sores, cough, loss of appetite, nausea/vomiting,
diarrhea and abdominal pain in the 8 weeks before AHI
diagnosis. With persistent lymphadenopathy or fatigue, ARS
resolution date was the end date of all other symptoms. We
present descriptive statistics of demographic characteristics and
ARS-related symptoms.
HIV sequence analysis
SGA and DNA sequence analysis were performed on the first
available specimens for 24 of 37 participants. Approximately
10,000–20,000 viral RNA copies were extracted using the
QIAamp viral RNA mini kit (Qiagen). HIV-1 RNA was reverse
transcribed to cDNA using Superscript III Reverse Transcriptase
(RT) System (Invitrogen.) The env gene was amplified using a
limiting dilution approach,[17,18,19] to exclude Taq polymerase-
induced errors and artifactual recombination, and to provide
proportional representation of each viral sequence.[15,20] PCR
products were directly sequenced. To ensure sequences reflected
single templates from in vivo populations, we excluded amplicons with
‘‘double peak’’ sequence chromatograms, indicating co-amplification
of .1 template. DNA sequences from participants 1, 2, 3, and 4 were
previously described in Keele et al.[15] Genbank accession numbers
are: EU578952-EU578997, EU576425-EU576470, FJ496009-
FJ496011, EU578998-EU579019, GU330247-GU331770, HQ-
908109-HQ908254.
DNA sequences were aligned using CLUSTAL W[21] and then
codon-aligned manually.[21] Sequence differences were visualized
using Neighbor-Joining trees (MEGA 4.0)[22] and Highlighter
nucleotide transition and transversion plots (www.hiv.lanl.gov) to
determine number of transmitted/founder viruses. G-to-A hyper-
mutants from apolipoprotein B mRNA editing enzyme, catalytic
polypeptide-like (APOBEC) signatures (www.hiv.lanl.gov) were
excluded. Markov Chain Monte Carlo Simulation (MCMC) using
Bayesian inference was used to estimate the infection date based
on number of viral generations using BEAST (Bayesian Evolu-
tionary Analysis by Sampling Trees v.1.5.3)[23] as previously
described [24] with an HKY substitution model; HIV-1
generation time of 1.6 days; and a substitution rate of
2.1661025. Average tree model root height was used to
determine the number of viral generations since infection with a
95% confidence interval (CI).
Analysis of plasma cytokine and chemokine levels
Plasma levels of thirteen cytokines/chemokines (interleukin (IL)-
1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12(p70), IL-13,
interferon (IFN)c, granulocyte-macrophage colony-stimulating
factor (GM-CSF) and tumor necrosis factor (TNFa) were
measured at enrollment in the HIV-seronegative control subjects,
and at time points from enrollment through week 24 in the AHI
subjects using a high-sensitivity human cytokine Lincoplex kit
(Millipore). Six factors (inducible protein [IP]-10, monocyte
chemotactic protein [MCP]-1, monokine induced by IFNc[MIG],
macrophage inflammatory protein [MIP]-1a, MIP-1band regu-
lated on activation, normal T cell-expressed and -secreted
[RANTES]) were measured by Bio-plex cytokine assay (Bio-
Rad). Data were acquired on a Luminex-100 system and analyzed
using Bio-Plex Manager software, v4.1 (Bio-Rad). Plasma levels of
three cytokines were determined by ELISA: IL-15 using a high-
sensitivity chemiluminescent assay (R&D Systems) and IFNband
IL-18 using colourimetric ELISAs (R&D Systems and Invitrogen,
respectively). All samples were assayed in duplicate. Data on
chemokine/cytokine elevations during AHI in plasma donors were
used for comparison.[25]
Enrollment and week 16/24 chemokine/cytokine levels in AHI
subjects were compared with those in the seronegative controls.
Cytokine/chemokine levels in seronegative control subjects and
treated and untreated AHI subjects were compared using a
Kruskal-Wallis non-parametric test. These data were analyzed
using Prism (version 4, GraphPad Software, Inc.) and R statistical
software. Given the high chance of type 2 errors (false negative
results) being incurred if p values were adjusted to correct for the
number of comparisons made, the p values shown are raw rather
than adjusted values. However, to reduce the occurrence of type
1 errors (i.e. concluding that chance observations were real) only
test results with a p value of ,0.01 were considered to be
significant.
Results
Study Population
Between June 2006 and April 2008, 36 acutely infected
participants were enrolled onto the CHAVI 001 study; 22 were
Cross-Sectional Detection of Acute HIV Infection
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community medical providers. Most were men who have sex with
men (MSM) with a median age of 25 years (Table 1). The median
viral load at diagnosis was 332,879 copies/ml and the median
highest observed viral load was 592,690 copies/ml. For 81% of
subjects, the initial viral load was the highest. The median CD4
count at enrollment was 541 cells/mm
3 and median nadir CD4
count was 487 cells/mm
3 occurring at enrollment in 20 (54%)
subjects. Among 4 (11%) participants who remained seronegative
at enrollment, the median maximum viral load was higher at
2,572,861 copies/ml, and the median CD4 count was lower at
327 cells/mm.
3
Nearly all participants (95%) experienced $1 ARS-related
symptom. The median number of symptoms was 5 (range 0–13.)
Fever was most commonly reported (70%); approximately one-
third had gastrointestinal symptoms and one-quarter reported
odynophagia. The median symptom duration was 13 days (range
2–48). The median time from symptom onset to the highest
observed viral load was 13 days (range -10–47 days). In linear
regression analysis, number of symptoms (p=0.03; 95% CI, 0.02–
Table 2. Comparison of the estimated the date of infection based on Bayesian Evolutionary Analysis by Sampling Trees (BEAST)
versus acute retroviral symptom onset.
Participant Number Number of amplicons BEAST days post-infection Days post-infection (Symptoms)
d
(95% CI)
c
2 40 19 (7, 35) 15
3 45 38 (19, 63) 25
4 22 27 (11, 46) 17
6 19 31 (12, 54) 26
7 24 43 (15, 81) 51
10 44 21 (11, 33) 21
11 37 39 (19, 63) 33
14 11 23 (3, 50) 19
16 8 35 (6, 77) 26
19 17 7 (1, 18) 17
23 28 50 (22, 85) 29
24 23 21 (5, 42) 30
25 28 20 (7, 35) 18
29 36 69 (31, 116) 41
31 38 49 (28, 73) 32
aSymptom onset minus 14 days.
bSample date minus BEAST estimated days post-infection.
cBEAST estimated days post-infection from time of sampling.
dSample date minus symptom estimated infection date.
doi:10.1371/journal.pone.0019617.t002
Figure 1. Timeline of AHI: estimated HIV exposure, symptom onset, presentation to care, AHI diagnosis and enrollment in subjects
with a narrow window of exposure based on self-report. A narrow window of exposure is defined as all patients with high or medium
exposure date confidence (n=6), plus patients with a one-time exposure in the 8 weeks prior to diagnosis with a partner of unknown status (n=4).
doi:10.1371/journal.pone.0019617.g001
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associated with higher log10HIV RNA.
Subjects had the option of beginning ART, and 27 (73%)
elected to start treatment. Treated participants were older,
median age of 32 (range 18–66) versus 22 years (range 17–56)
among untreated acutes (p=.005). The number of ARS
symptoms was higher among treated versus untreated acutes;
median of 6 (range 1–13) versus 4 (range 0–8), respectively
(p=.01). There were no statistically significant differences
between treated and untreated participants regarding report of
$2 symptoms, symptom duration, highest viral load or nadir
CD4 count.
Predicted time of acquisition of HIV
Given the desire to identify subjects as quickly as possible after
infection, we attempted to estimate the date of exposure. Over one-
third were evaluated at a medical facility prior to AHI diagnosis,
representing missed opportunities for earlier diagnosis. Figure 1
depicts the timeline of exposures, symptom onset, presentation-to-
care, AHI diagnosis and enrollment for subjects with a relatively
narrow exposure window. From the date of blood draw, the mean
turn-around time for NAT pooling results during the study period
was 12 days (range 2 to 41). Four transmission pairs were confirmed
by SGA and DNA sequencing; however, multiple sexual exposures
occurred with two confirmed transmission partners (not shown),
precluding establishment of an exposure date. Subject 3 (Figure 1)
reported only one exposure on the date of enrollment. Subject 1
reportedaone-timeexposurewithaconfirmedtransmissionpartner
occurring 16 days before symptom onset. Using the midpoints of
exposure windows for 7 of 10 subjects with relatively narrow
exposure windows (subjects 3, 4 and 6 were excluded), median
estimated exposure to HIV occurred 14 days before symptom onset
(range 9–21 days, IQR 12–17).
The median time from symptom onset to initial presentation-to-
care was 3.5 days (range -16–47); 3 participants developed
symptoms after initial presentation. The median time from
symptom onset to AHI diagnosis was 6 days (range -10–47) and
to enrollment was 23 days (range 5–60). Notably, date of AHI
diagnosis reflects the date of the first test result indicating AHI, and
not when individuals are notified of their result. Accordingly, the
delay from AHI diagnosis to enrollment reflects the time required to
perform and confirm NAT pooling, trace and notify suspected AHI
cases, and arrange for evaluation by a provider. There were no
differences between median time from AHI diagnosis to enrollment
between participants diagnosed through the NC STAT program
and those referred from private providers. Among 4 seronegative
participants at enrollment, median time from symptom onset to
enrollmentwasshorter at 13days(range8–24). However,time from
symptom onset to observed seroconversion among enrollment
seronegatives was longer at 22 days (range 15–37) versus 17 days
(range -10–41) among enrollment seropositives.
Extent of viral sequence diversification
To confirm AHI status, viral diversification was assessed in 24
participants. On average, 29 full-length env amplicons were
generated per subject. Given reasonable assumptions regarding
viral mutation rate and generation time,[26] time since infection
(time to most recent common ancestor [TMRCA]) was estimated
using Bayesian molecular clock models. Recent publications
highlight their use to model inter-continental HIV-1 spread,[27]
subtype evolution,[28] and evolution during AHI.[26] We
compared estimated-date-of-infection from SGA-derived sequenc-
es using BEAST to estimated-date-of-infection based on symptom
onset, the latter defined as 14 days prior to the first ARS symptom
(Table 2). Molecular clock models assume single variant
transmission, as multiple variant transmissions overestimate
TMRCA.[15,26] Of 24 participants sequenced, 9 demonstrated
multiple transmitted/founder viruses. Four of 9 subjects with
multiple variants and 14 of 15 with single variants were self-
reported MSM. As expected, BEAST overestimated TMRCA
with multiple transmitted/founder viruses (not shown).
BEAST estimates of single variant transmissions (695% CI)
overlapped with estimated-date-of-infection based on symptoms.
The interval between infection and participant sampling per
symptom onset ranged from 17–51 days (mean 27). Similarly,
estimated TMRCA using BEAST ranged from 7–69 days (mean
33). Estimated-dates-of-infection based on symptoms versus
BEAST had a positive correlation with R
2=0.54 for all 15
participants (Figure 2). Analyzing 14 participants with estimated-
dates-of-infection within 4 weeks of symptom onset increased the
correlation coefficient (R
2=0.72), suggesting BEAST estimates are
most accurate when combined with more recent clinical data,
possibly due to recall bias.
Plasma cytokine and chemokine levels
Prior analysis of plasma donor samples from eclipse and viral
expansion phases demonstrated cytokine/chemokine elevations as
viremia increased.[25] Similar analysis of plasma cytokine/
chemokine levels was performed on sequential samples from 23
CHAVI AHI subjects. Figure 3 shows examples of data for four
cytokines in one plasma donor [25] and two CHAVI AHI
subjects. Elevations in cytokines such as IFN-a and IL-15,
transiently up-regulated before peak viremia,[25] were rarely
captured in CHAVI AHI subjects where enrollment sometimes
occurred prior to/near peak viremia (subject B), but usually
occurred during the viral contraction phase (subject C). Elevations
were more commonly observed in analytes with rapid but
sustained increases during AHI, such as IL-18; or in analytes
up-regulated at/after peak viremia, such as IL-1b. This was
emphasised by comparing enrollment analyte levels in 22 AHI
subjects (one enrollment sample was missing) and 21 CHAVI
HIV-seronegative controls (Table 3). Only 10 analytes were
significantly higher (p,0.01) in AHI participants: IP-10 and IL-18,
which exhibit rapid, sustained increases in AHI;[25] IL-6, IL-10
and IFNc, which also exhibited sustained, although somewhat
slower, increases in AHI in the plasma donors; MIG, not analyzed
Figure 2. Estimated dates of infection based on symptom onset
(x axis) vs. BEAST (y axis) in 15 patients with single variant
transmissions. Infection dates were inferred by subtracting 14 days
from symptom onset and compared to BEAST calculations relative to
sampling of blood plasma for SGA env sequence generation. The slope
of the line is 1.16660.2995 with R
2=0.54 for all 15 patients.
doi:10.1371/journal.pone.0019617.g002
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19617Figure 3. Viral loads and plasma levels of IFNa, IL-15, IL-18 and IL-1bin sample time courses from three subjects acutely infected
with HIV. A is a US plasma donor, whose sample time course is plotted in days and is aligned relative to the time (designated day 0) when the
plasma viral load first reached 100 copies/ml (i.e. the start of the viral expansion phase). B and C are CHAVI 001 subjects, whose sample time courses
are plotted in weeks, and are aligned relative to the time of study enrollment (week 0). Subject B started ART just after study enrollment, as indicated
by the black arrow. Viral load data is plotted as open squares joined by dotted lines, and is expressed as log10 RNA copies/ml. Data for each cytokine
is plotted as filled symbols joined by solid lines, and is expressed as pg/ml.
doi:10.1371/journal.pone.0019617.g003
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showed relatively late increases in approximately half of plasma
donors (where sampling frequently ended around peak vire-
mia.)[25] Although most AHI participants were not enrolled early
enough to capture cytokine elevations during viral expansion, this
cohort provides a complementary picture of analyte levels later in
AHI.
This cohort also provided an opportunity to determine levels at
which plasma analytes stabilise in AHI. Comparison of analyte
levels at week 16/24 post-enrollment in 18 acute subjects (11 of
whom started ART shortly after enrollment and 7 of whom
remained untreated) with those in the 21 seronegative controls
sampled at enrollment (Table 3) showed that IL-18 was
significantly elevated (p,0.01) among AHI subjects, whilst levels
of several other analytes (IL-1b, IL-2, IL-7, IL-15 and IFNc)
exhibited differences of lower significance (p,0.05) between the
two groups, and others (IL-6, IL-10 and IL-12) trended toward
higher levels in AHI subjects, possibly failing to reach statistical
significance because of small group sizes. In contrast to other
analytes that were elevated in acute subjects versus controls at 16–
24 weeks, levels of MIP-1bwere slightly reduced (p,0.05). These
results indicate that systemic levels of many cytokines/chemokines
stabilise in the near normal range after the AHI cytokine storm,
but a subset remain elevated into early infection.
To evaluate whether severity of AHI symptoms influenced ART
initiation, possibly related to the magnitude and/or duration of
cytokine/chemokine levels, we compared enrollment analyte levels
in 21 seronegative participants, 10 treated AHI participants, and
12 untreated AHI participants. Data for the 10 analytes
significantly elevated at enrollment in AHI participants compared
to seronegative controls are shown (Figure 4A). There was a trend
towards higher IL-18 levels and lower MIG and IP-10 levels in
treated versus untreated participants, although no difference
between these groups reached statistical significance, possibly
due to the low sample sizes.
We also compared analyte levels between seronegative controls
(at enrollment) and treated and untreated AHI subjects at week
16–24. Data for 10 analytes is shown (Figure 4B). Only IP-10
differed significantly (p,0.01) between treated and untreated
participants at week 16/24, although there were also trends for
levels of other analytes, including IL-7 and MIG, to be higher in
untreated AHI participants than in treated subjects that did not
Table 3. Median plasma levels of 22 cytokines and chemokines at enrollment and week 16–24 in CHAVI 001 AHI subjects and HIV-
seronegative controls.
Analyte
HIV negative enroll-
ment median (IQR)
a AHI enrollment
P - enrollment
c
(95% CI) AHI week 16–24 P - week 16–24
c
median (IQR)
b median (IQR)
d (95% CI)
IL-1b 0.20 (0.07–0.93) 3.57 (0.50–7.73) 0.0003 (0.39–5.45) 2.07 (0.11–7.73) 0.015 (,0.01–5.39)
IL-2 3.72 (1.03–6.07) 19.94 (11.41–63.92) 0.0001 (8.57–49.32) 29.7 (1.00–56.56) 0.040 (,0.01–39.70)
IL-4 64.29 (6.36–241.04) 106.58 (18.40–244.98) 0.496 (-60.21–96.17) 72.07 (8.08–175.62) 0.778 (-107.04–65.24)
IL-5 0.67 (0.07–1.22) 1.13 (0.32–2.40) 0.324 (-0.27–1.10) 0.6 (0.26–2.43) 0.660 (-0.50–0.92)
IL-6 4.02 (0.66–16.91) 24.91 (11.89–34.03) 0.003 (6.18–25.98) 13.63 (2.88–33.32) 0.139 (-0.59–22.93)
IL-7 1.10 (0.32–2.93) 7.56 (0.98–14.31) 0.004 (0.65–10.21) 7.0 (0.76–18.19) 0.031 (,0.01–11.57)
IL-8 4.66 (2.02–10.32) 8.28 (3.54–13.34) 0.185 (-1.32–6.95) 4.19 (0.77–15.01) 0.933 (-3.40–7.10)
IL-10 5.26 (2.82–10.83) 19.61 (11.10–45.92) 0.002 (5.08–25.56) 18.63 (3.39–31.75) 0.317 (-2.50–21.35)
IL-12 (p70) 1.82 (0.92–6.25) 11.9 (1.68–34.93) 0.080 (-0.03–23.70) 11.45 (1.58–32.43) 0.167 (-0.52–21.33)
IL-13 36.49 (6.83–125.47) 49.40 (23.63–101.36) 0.827 (-38.99–38.76) 28.84 (4.69–66.58) 0.414 (-61.83–18.13)
IFNc 2.24 (1.60–5.43) 14.55 (4.94–39.59) 0.004 (1.31–24.88) 14.72 (1.60–51.08) 0.043 (,0.01–28.90)
TNFa 4.67 (3.48–6.38) 7.33 (5.22–9.77) 0.060 (-0.12–4.12) 7.42 (3.81–8.85) 0.172 (-1.26–3.83)
GM-CSF 4.72 (2.35–12.60) 15.43 (5.50–50.54) 0.009 (1.42–33.63) 4.32 (1.25–18.21) 0.810 (-2.45–11.39)
MCP-1 41.04 (27.36–57.98) 43.77 (29.64–82.15) 0.671 (-16.40–24.72) 35.67 (10.24–72.66) 0.490 (-27.33–15.67)
MIG 295.85 (173.71–453.99) 1164.01 (391.36–1926.59) ,0.0001 (286.18–1522.60) 353.35 (115.31–1031.00) 0.564 (-126.17–536.19)
MIP1a n/c
e n/c n/c n/c n/c
MIP1b 36.81 (30.69–65.81) 33.88 (20.18–49.09) 0.123 (-25.71–2.98) 23.48 (14.28–46.86) 0.041 (227.96–(20.84))
RANTES 300.28 (223.41–985.06) 416.22 (261.53–749.84) 0.971 (-238.57–195.57) 298.78 (152.37–396.11) 0.172 (-583.07–57.67)
IP-10 253.05 (177.16–334.77) 470.5 (286.56–718.71) 0.003 (72.13–359.48) 150.32 (97.61–357.42) 0.172 (-149.20–33.62)
IFNa 1.563
f (1.56–1.56) 6.64 (1.56–96.75) 0.024 (,0.01–42.4) 1.56 (1.56–46.5) 0.122 (,0.01–16.4)
IL-18 161.60
f (90.32–270.99) 555.5 (316.07–883.01) 0.0001 (198.55–635.24) 390.17 (262.25–511.40) 0.001 (104.76–357.47)
IL-15 0.84
g (0.79–0.89) 1.26 (0.92–1.61) 0.035 (,0.01–0.58) 1.15 (0.89–1.51) 0.04 (0.02–0.6)
aMedian analyte levels (pg/ml) in 21 HIV-seronegative control subjects. The 25
th and 75
th percentiles of the range are also given (IQR).
bMedian analyte levels (pg/ml) in 22 AHI subjects. The 25
th and 75
th percentiles of the range are also given (IQR).
cAnalyte levels in the seronegative controls at enrollment were compared to analyte levels in the AHI subjects at enrollment and week 16–24 using a Mann-Whitney U
test. The p values are shown; significant values (p,0.01) are highlighted in bold. 95% confidence intervals are also shown (95% CI).
dMedian analyte levels (pg/ml) in 18 AHI subjects. The 25
th and 75
th percentiles of the range are also given (IQR).
en/c = not calculated (MIP-1a levels in the majority of samples were below the limit of assay detection).
fFor IFNa and IL-1,8 n=14.
gFor IL-15, n=10.
doi:10.1371/journal.pone.0019617.t003
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PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19617Figure 4. Comparative analysis of plasma levels of 10 selected analytes at enrollment and week 16–24 in AHI subjects commencing
ART, AHI subjects choosing not to start ART and HIV-seronegative controls. Plasma levels of 22 cytokines and chemokines were measured
in sample time courses from a total of 23 AHI subjects and 21 HIV seronegative controls (Neg). Data for ten analytes (IL-1b, IL-2, IL-7, IFNc, GM-CSF,
MIG, MIP-1b, IP-10, IL-18 and IL-15, each expressed as pg/ml plasma) is shown at A) the enrollment time point (prior to commencement of therapy),
when samples were available from 10 CHAVI 001 AHI subjects who chose to commence ART after the enrollment time point (AHI - T) and 12 AHI
subjects who chose to remain untreated (AHI - UT) and B) week 16 or 24, when samples were available from 11 CHAVI 001 AHI subjects who chose to
commence ART after the enrollment time point (AHI - T) and 7 AHI subjects who chose to remain untreated (AHI - UT). In both A and B, data are also
shown from 21 HIV-seronegative subjects (sampled at the enrollment time point), except for IL-18 where n=14 and IL-15 where n=10. Each symbol
represents data for an individual subject, and horizontal lines represent the median analyte level in the subject groups. Bars at the top of each graph
show statistically significant differences between groups (p,0.01; Kruskal-Wallis non-parametric test).
doi:10.1371/journal.pone.0019617.g004
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of subjects per group.
Discussion
AHI is a critical phase of infection during which irrevocable
damage to the immune system[29,30] and substantial secondary
transmission occurs.[10,11,12] The goal of this study was to
identify AHI participants using cross-sectional screening, and to
characterize clinical, immunological and virological evolution of
AHI detected via this strategy. The results demonstrate the
challenge in finding and rapidly enrolling patients very early in
AHI, as only 4 participants remained seronegative at enrollment.
The time from symptom onset to seroconversion was longer
among those remaining seronegative at enrollment, suggesting
seropositivity may be an inaccurate marker of the degree of
‘‘acuteness.’’ We anticipated cross-sectional screening would
identify early HIV acquisition and many participants would be
asymptomatic. However, nearly all participants were symptomatic
and sought care and/or HIV testing due to symptoms. Indeed,
over one-third were seen at least once prior to diagnosis, reflecting
symptom non-specificity and that the clinical suspicion and risk
assessment for AHI remains low among practitioners. Notably, the
overall delay from symptom onset to the date of testing for AHI
was relatively short among participants (median 6 days) compared
to the delay from date of testing for AHI to enrollment (median 16
days). The majority of the latter delay results from a median turn-
around of 12 days for confirmed NAT pooling results.
In this study, we used sequencing to examine viral diversifica-
tion and confirmed the short duration of infection. Using SGA to
estimate infection dates based on number of viral generations,
BEAST results correlated well with estimated-date-of-infection per
symptom report in subjects with single variant transmissions. To
our knowledge, this is the first report of using molecular clock
modeling in conjunction with symptom data to estimate date of
HIV acquisition. The results validate using molecular clocks to
confirm AHI with clinical data, and to estimate HIV transmission
dates without specific exposure or symptom information. Findings
are consistent with prior studies with well-described HIV exposure
dates,[31,32] and support use of 14 days prior to symptom onset to
estimate HIV transmission dates.
Previous retrospective study of samples obtained from frequent
plasma donors before, during and after HIV acquisition
demonstrated elevations in multiple cytokines/chemokines during
viral expansion.[25] A similar cytokine storm was not observed in
this prospective study, suggesting enrollment occurred after peak
levels of viremia and cytokines. However, differences were
observed between the AHI subjects and seronegative controls in
levels of some cytokines/chemokines that are elevated for a
relatively sustained period during the acute phase (i.e. IL-18, IP-
10, IFNc, IL6 and IL-10) and in other analytes that are increased
later in AHI (i.e. IL-1b, IL-2, IL-7 and GM-CSF). In line with
these observations, a recent study in a high risk female cohort
reported significant elevations in IL-1, IL-2, IL-7 and IP-10 at a
median of 6 weeks post-HIV-infection.[33] More pronounced
differences are likely not demonstrated in our cohort due to the
delay in confirming AHI diagnosis as above.
Increased immune activation and cytokine levels during AHI
are likely instrumental in inducing clinical symptoms, which
typically begin during viral expansion when there are very high
circulating levels of cytokines and chemokines.[25] In our study,
symptoms frequently persisted after the peak in viremia and
cytokine levels; however, some analytes including IL-1b(an
endogenous pyrogen) were elevated at enrollment (coinciding
with the viral contraction phase) and may have contributed to the
prolonged symptom duration observed in this cohort. It seemed
possible that symptom severity would influence subjects’ decision
to commence ART. Although the number of symptoms reported
by participants who initiated ART was higher, there were no
statistically significant differences in those with and without ART.
However, the small number of participants in the groups limits this
analysis, and other factors (age) may also play a significant role.
We observed no significant difference in plasma cytokine/
chemokine levels at enrollment in treated versus untreated
subjects, but cannot exclude that more intense cytokine responses
may have occurred before enrollment in treated subjects.
ART in early HIV has not demonstrated substantial long-term
clinical benefit;[34,35] however, studies suggest early ART could
reduce the viral reservoir[36,37] and HIV transmission.[38] We
noted minimal effect of ART on levels of cytokines/chemokines at
week 16–24 possibly due to the delay from presentation-to-care, to
diagnosis and for referral. Accordingly, ART typically commenced
after peak viremia, when the cytokine storm and viral replication
were subsiding. However, analysis of the effects of ART initiation in
AHI on levels at which cytokines/chemokines stabilize in early
infection was not the primary goal of this study, and it remains
possible that we would have detected more differences in cytokine/
chemokine levels in ART-treated and untreated subjects if our
subject groups had been larger. Previous studies have reported that
ART initiation in chronic infection is associated with a decline in
circulating levels of cytokines/chemokines including IL-1b, IL-6,
IL-10, TNFa and alpha/beta chemokines [39,40], although other
studies reported conflicting findings, such as no effect of ART on
circulating levels of IL-6 and C-reactive protein.[41,42] Further
work is required to address whether these divergent results may be
attributable to effects of the timing of ART initiation (during acute,
early chronic or later-stage infection).
It is regrettable that AHI detection in the general population
remains uncommon since interventions during AHI could lead to
both personal and public health benefit, with as many as 39% of
new HIV cases ascribed to untreated and unrecognized AHI.[43]
Our findings utilizing cross-sectional screening to detect AHI
emphasize that more expedient diagnostic methods for detection
of AHI are urgently needed, such as point-of-care virological
assays and/or algorithms incorporating 4
th generation EIA assays.
More rapid diagnosis of AHI with rapid entry into care following
detection would allow individuals to fully benefit from treatment
and secondary prevention, and the study of the earliest
immunological events in AHI to inform treatment and vaccine
strategies. In the interim, formal guidelines for the management of
such patients await further results of clinical and translational
studies.[44]
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